An Open-label Feasibility Trial of Adjunctive Telmisartan in Patients With Treatment Resistant Schizophrenia
Latest Information Update: 07 Mar 2022
At a glance
- Drugs Telmisartan (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Biomarker; Therapeutic Use
Most Recent Events
- 07 Feb 2022 Status changed from active, no longer recruiting to discontinued.
- 15 Jan 2021 Planned End Date changed from 1 Oct 2020 to 31 Dec 2021.
- 24 Mar 2020 Planned End Date changed from 1 May 2020 to 1 Oct 2020.